Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

NCT02292537
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 12 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

NCT03765762
View directory record Official record
Conditions
Severe Alzheimer Disease
Interventions
GRF6019, Placebo
Drug · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
6
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 23, 2026, 11:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Spark of Duval Intervention

NCT04044027
View directory record Official record
Conditions
Teen Pregnancy Prevention
Interventions
S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression

NCT01423773
View directory record Official record
Conditions
Ocular Comfort
Interventions
Lotrafilcon A test contact lens, Lotrafilcon A control contact lens, Ultra-High Resolution Optical Coherence Tomographer (OCT)
Device
Lead sponsor
CIBA VISION
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

NCT03417505
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
Device
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

NCT04382651
View directory record Official record
Conditions
COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Chula Vista, California • Glendale, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional

Tailoring a Lifestyle Intervention to Address Obesity Disparities Among Men

NCT03037502
View directory record Official record
Conditions
Weight Loss, Obesity
Interventions
Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
35 Years to 64 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study: Manometry With & Without Lidocaine

NCT03349112
View directory record Official record
Conditions
Normal
Interventions
4% Lidocaine Spray, 2% Viscous Lidocaine
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 23, 2026, 11:55 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 23, 2026, 11:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fluid Loading Countermeasures

NCT06467812
View directory record Official record
Conditions
Healthy
Interventions
Salt Tablets, Electrolyte Solution
Dietary Supplement
Lead sponsor
National Aeronautics and Space Administration (NASA)
Federal
Eligibility
25 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 23, 2026, 11:55 PM EDT
Terminated Phase 4 Interventional Results available

Ketamine for Pain in the Emergency Department

NCT03896230
View directory record Official record
Conditions
Acute Pain
Interventions
Ketamine Injectable Product
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of PTI-125 in Healthy Volunteers

NCT03784300
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Infusion of CAP-1002 in Patients With COVID-19

NCT04623671
View directory record Official record
Conditions
Covid19
Interventions
CAP-1002, Placebo
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family-centered Mental Health Promotion Intervention

NCT04453709
View directory record Official record
Conditions
Stress, Psychological, Stress, Physiological, Anxiety, Depression
Interventions
Problem Management Plus for Immigrants at family settings, Talk program with Community Support Service Pamphlet (CSS)
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

NCT03782792
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 11:55 PM EDT
Recruiting Phase 2 Interventional

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

NCT07202000
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Activin ligand-trap biological therapy, Placebo, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Brain Dopamine Function in Human Obesity

NCT03648892
View directory record Official record
Conditions
Obesity, Healthy Volunteers, Overweight
Interventions
[c11] raclopride, [18F]fallypride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 11:55 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of CPT Versus ART Versus WL

NCT03384706
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Processing Therapy (CPT), Accelerated Resolution Therapy (ART)
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 23, 2026, 11:55 PM EDT
Completed No phase listed Observational Results available

In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.

NCT00788255
View directory record Official record
Conditions
Anesthesia
Interventions
Final exogenous oxytocin concentration=22.5 μU/mL, Final exogenous oxytocin concentration=30.1μU/mL, Final exogenous oxytocin concentration=32.9μU/mL
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

NCT01982747
View directory record Official record
Conditions
Healthy
Interventions
MGN-Placebo, Placebo-MGN
Drug
Lead sponsor
Mologen AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 23, 2026, 11:55 PM EDT
Completed Not applicable Interventional

Radiation Therapy Plan Quality Improvement Using Ideal Theoretical Isodose Distribution

NCT04782726
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Software Solution for Radiation Therapy Treatment, Radiation therapy
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 23, 2026, 11:55 PM EDT